This a prospective observational registry of patients with psoriasis (PsO). Longitudinal data will be collected via questionnaires from patients at a baseline visit and then approximately every 3 to 6 months for follow-up. The patient registry will focus on tracking patient outcome measures related to psoriasis.
The primary objective of this study is to identify risk factors for the development of cardiovascular disease, diabetes, and PsA among patients with psoriasis
Psoriasis is a chronic inflammatory skin condition that affects 2-3% of US adults. Psoriasis has a number of different phenotypes (i.e., plaque, guttate, erythrodermic, inverse, and pustular).(1) Plaque psoriasis is the most common. While approximately half of patients with psoriasis have mild disease (less than 3% of their body surface area, BSA), almost half of patients have moderate (3-10% of their BSA) or severe (>10% BSA).(2, 3)
Psoriasis has a significant impact on patients’ lives, even when mild. It can be itchy or painful and in severe cases can crack and bleed. Many patients have had the experience of others being afraid of them or treating them as ‘diseased’ because of the skin lesions, thinking that it may be infectious. Moreover, it has a significant impact on emotional wellbeing – social isolation (due to embarrassment or not feeling well), depression and anxiety are very common.(2, 4-7) In this study, we will examine the ways in which psoriasis impacts patients and how they manage the impact of the disease on their lives.
There are now many treatments for psoriasis that can dramatically improve not only the skin but also these psychosocial outcomes. Unfortunately, however, many patients are under treated, even those with severe disease. Even when treated, many patients are not satisfied with their current treatment and certain treatments may have more treatment burden than others.(2, 8-10) In this study, we will examine treatment of psoriasis in the United States as well as patients’ experience with treatment burden and their overall treatment satisfaction. We will also utilize the available data to compare among available treatments.
Beyond the skin findings, psoriasis is associated with systemic inflammation and as a result of this inflammation, early atherosclerosis, major adverse cardiovascular events (MACE) such as myocardial infarction, stroke and cardiovascular death, as well as increased mortality rates compared to the general population.(1) Psoriasis is additionally associated with a number of other comorbidities including an increased risk for diabetes. Little is known about which patients with psoriasis will develop these comorbidities or have a higher risk for poor outcomes.(5) In this study, we will examine risk factors for development of these common comorbidities.
Among the most common comorbidities associated with psoriasis is psoriatic arthritis (PsA), affecting 20-30% of patients over the course of their lifetime.(11) PsA is a heterogeneous inflammatory musculoskeletal disease that can cause permanent joint damage and disability. Little is known about how to predict which patients with psoriasis will develop PsA.(12-15) In this study, we will examine risk factors for development of psoriatic arthritis.